News

Coronavirus: What Amyloidosis Patients Should Know
With rising concerns about COVID-19, ARC is providing the following information and resources detailing preventative measures and recommendations for the amyloidosis community. (more…)
Read More
HTA Toolkit for Patient organizations
ARC Launches HTA Toolkit for Patient Advocates
ARC has published a Health Technology Assessment Toolkit to equip patients and patient groups within Europe, as well as globally, with the tools to advocate on behalf of themselves and other patients for access to new treatments. (more…)
Read More
ARC attends inaugural AfPA meeting
On February 8, 2020, ARC’s Manager of Healthcare and Education, Lori Bulpett, attended the inaugural Rare Disease Working Group Meeting, hosted by the Alliance for Patient Access (AfPA), in Washington, DC. The meeting's focus was on amyloidosis and the various...
Read More
ARC’s Inaugural Masterclass a Success!
In early January, ARC hosted its first Masterclass, 'Mastering the Art and Science of Amyloidosis.' Over 75 healthcare providers were in attendance for the broad range of topics and comprehensive training, taught by leading amyloidosis experts. (more…)
Read More
ARC's 2019 Achievements
ARC is Poised for Great Things in 2020
2019 was a year of great accomplishments for the Amyloidosis Research Consortium (ARC), and we are grateful to all of you who have so generously supported our efforts to accelerate the pace of development of drugs to treat and improve...
Read More

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
arc@arci.org

ARC is a 501(c)(3) nonprofit organization